Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway

Journal of Cellular Physiology

Volumn 228, Issue 1, 2013, Pages 198-206

  Spina, Annamaria ^a   Sorvillo, Luca ^a   Di Maiolo, Francesca ^a   Esposito, Antonietta ^a   D'Auria, Raffaella ^a   Di Gesto, Davide ^a   Chiosi, Emilio ^a   Naviglio, Silvio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; BETA3 INTEGRIN; CASPASE 3; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATE; PIFITHRIN ALPHA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RAP1 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE TARGETING; HUMAN; HUMAN TISSUE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANTIBIOTICS, ANTINEOPLASTIC; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; DOXORUBICIN; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OSTEOSARCOMA; PHOSPHATES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84867181885     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24124     Document Type: Article

References (57)

1. Alkhalaf M, Jaffal S. 2006. Potent antiproliferative effects of resveratrol on human osteosarcoma SJSA1 cells: Novel cellular mechanisms involving the ERKs/p53 cascade. Free Radic Biol Med 41: 318-325.
2. Ballif BA, Blenis J. 2001. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 12: 397-408.
3. Bednarski BK, Baldwin AS, Jr., Kim HJ. 2009. Addressing reported pro-apoptotic functions of NF-kappaB: Targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin. PLoS ONE 4: e6992.
4. Bradford MM. 1976. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72: 248-254.
5. Cagnol S, Chambard JC. 2010. ERK and cell death: Mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J 277: 2-21.
6. Camalier CE, Young MR, Bobe G, Perella CM, Colburn NH, Beck GR, Jr. 2010. Elevated phosphate activates N-ras and promotes cell transformation and skin tumorigenesis. Cancer Prev Res 3: 359-370.
7. Chambard JC, Lefloch R, Pouyssegur J, Lenormand P. 2007. ERK implication in cell cycle regulation. Biochim Biophys Acta 1773: 1299-1310.
8. Chen JT, Fong YC, Li TM, Liu JF, Hsu CW, Chang CS, Tang CH. 2008. DDTD, an isoflavone derivative, induces cell apoptosis through the reactive oxygen species/apoptosis signal-regulating kinase 1 pathway in human osteosarcoma cells. Eur J Pharmacol 597: 19-26.
9. Chou AJ, Geller DS, Gorlick R. 2008. Therapy for osteosarcoma: Where do we go from here? Paediatr Drugs 10: 315-327.
10. Cory S, Adams JM. 2002. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2: 647-656.
11. Dai X, Ma W, He X, Jha RK. 2011. Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Med Sci Monit 17: RA177-RA190.
12. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B. 1994. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174.
13. Ganjavi H, Gee M, Narendran A, Parkinson N, Krishnamoorthy M, Freedman MH, Malkin D. 2006. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: Sensitization to cisplatin and doxorubicin. Cancer Gene Ther 13: 415-419.
14. Gewirtz DA. 1999. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741.
15. Giordano A, Rossi A, Romano G, Bagella L. 2007. Tumor suppressor pRb2/p130 gene and its derived product Spa310 spacer domain as perspective candidates for cancer therapy. J Cell Physiol 213: 403-406.
16. Graat HC, Carette JE, Schagen FH, Vassilev LT, Gerritsen WR, Kaspers GJ, Wuisman PI, van Beusechem VW. 2007. Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53. Mol Cancer Ther 6: 1552-1561.
17. Gutierrez ME, Kummar S, Giaccone G. 2009. Next generation oncology drug development: Opportunities and challenges. Nat Rev Clin Oncol 6: 259-265.
18. Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M. 2010. Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 15: 615-634.
19. Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, Jikihara H, Mercola D, Murata Y. 1999. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 274: 31648-31654.
20. Hedström E, Issaeva N, Enge M, Selivanova G. 2008. Tumor-specific induction of apoptosis by a p53-reactivating compound. Exp Cell Res 315: 451-461.
21. Huang G, Mills L, Worth LL. 2007. Expression of human glutathione S-transferase P1 mediates the chemosensitivity of osteosarcoma cells. Mol Cancer Ther 6: 1610-1619.
22. Jackson MW, Agarwal MK, Agarwal ML, Agarwal A, Stanhope-Baker P, Williams BR, Stark GR. 2004. Limited role of N-terminal phosphoserine residues in the activation of transcription by p53. Oncogene 23: 4477-4487.
23. Khoshniat S, Bourgine A, Julien M, Weiss P, Guicheux J, Beck L. 2011. The emergence of phosphate as a specific signaling molecule in bone and other cell types in mammals. Cell Mol Life Sci 68: 205-218.
24. Kim SY, Helman LJ. 2009. Strategies to explore new approaches in the investigation and treatment of osteosarcoma. Cancer Treat Res 152: 517-528.
25. Kim SH, Nagalingam A, Saxena NK, Singh SV, Sharma D. 2010. Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3. Carcinogenesis 32: 359-367.
26. Kumar P, Coltas IK, Kumar B, Chepeha DB, Bradford CR, Polverini PJ. 2007. Bcl-2 protects endothelial cells against gamma-radiation via a Raf-MEK-ERK-survivin signaling pathway that is independent of cytochrome c release. Cancer Res 67: 1193-1202.
27. Le Tourneau C, Diéras V, Tresca P, Cacheux W, Paoletti X. 2010. Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents. Target Oncol 5: 65-72.
28. Li X, Zhao Y, Wu WK, Liu S, Cui M, Lou H. 2011. Solamargine induces apoptosis associated with p53 transcription-dependent and transcription-independent pathways in human osteosarcoma U2OS cells. Life Sci 88: 314-321.
29. Lopez-Heredia MA, Kamphuis GJ, Thüne PC, Öner FC, Jansen JA, Walboomers XF. 2011. An injectable calcium phosphate cement for the local delivery of paclitaxel to bone. Biomaterials 32: 5411-5416.
30. Maran A, Shogren KL, Benedikt M, Sarkar G, Turner RT, Yaszemski MJ. 2008. 2-Methoxyestradiol-induced cell death in osteosarcoma cells is preceded by cell cycle arrest. J Cell Biochem 105: 1146.
31. Mazumder S, Plesca D, Almasan A. 2008. Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis. Methods Mol Biol 414: 13-1321.
32. Moll UM, Petrenko O. 2003. The MDM2-p53 interaction. Mol Cancer Res 1: 1001-1008.
33. Naviglio S, Mattecucci C, Matoskova B, Nagase T, Nomura N, Di Fiore PP, Draetta GF. 1998. UBPY: A growth-regulated human ubiquitin isopeptidase. EMBO J 17: 3241-3250.
34. Naviglio S, Spina A, Chiosi E, Fusco A, Illiano F, Pagano M, Romano M, Senatore G, Sorrentino A, Sorvillo L, Illiano G. 2006. Inorganic phosphate inhibits growth of human osteosarcoma U2OS cells via adenylate cyclase/cAMP pathway. J Cell Biochem 98: 1584-1596.
35. Naviglio S, Di Gesto D, Romano M, Sorrentino A, Illiano F, Sorvillo L, Abbruzzese A, Marra M, Caraglia M, Chiosi E, Spina A, Illiano G. 2009. Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells. Cancer Biol Ther 8: 1183-1190.
36. Naviglio S, Di Gesto D, Illiano F, Chiosi E, Giordano A, Illiano G, Spina A. 2010. Leptin potentiates antiproliferative action of cAMP elevation via protein kinase A down-regulation in breast cancer cells. J Cell Physiol 225: 801-809.
37. Naviglio S, Di Gesto D, Borrelli V, Forni M, Illiano F, D'Auria R, Sorrentino A, Chiosi E, Illiano G, Spina A. 2011. Novel molecular mechanisms by inorganic phosphate in osteosarcoma U2OS cells. Front Biosci E3: 1249-1258.
38. Nishioka C, Ikezoe T, Yang J, Yokoyama A. 2009. Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells. Apoptosis 14: 1108-1120.
39. Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. 2012. Sarcomas in TP53 germline mutation carriers: A review of the IARC TP53 database. Cancer 118: 1387-1396.
40. Oshima Y, Sasaki Y, Negishi H, Idogawa M, Toyota M, Yamashita T, Wada T, Nagoya S, Kawaguchi S, Yamashita T, Tokino T. 2007. Antitumor effect of adenovirus-mediated p53 family gene transfer on osteosarcoma cell lines. Cancer Biol Ther 6: 1058-1066.
41. Ottaviani G, Jaffe N. 2009. The etiology of osteosarcoma. Cancer Treat Res 152: 15-32.
42. Prié D, Beck L, Urena P, Friedlander G. 2005. Recent findings in phosphate homeostasis. Curr Opin Nephrol Hypertens 14: 318-324.
43. Raina K, Agarwal R. 2007. Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: Efficacy and mechanisms. Acta Pharmacol Sin 28: 1466-1475.
44. Szekeres T, Saiko P, Fritzer-Szekeres M, Djavan B, Jäger W. 2011. Chemopreventive effects of resveratrol and resveratrol derivatives. Ann N Y Acad Sci 1215: 89-95.
45. Takeda E, Taketani Y, Sawada N, Sato T, Yamamoto H. 2004. The regulation and function of phosphate in the human body. Biofactors 21: 345-355.
46. Tanzawa Y, Tsuchiya H, Shirai T, Nishida H, Hayashi K, Takeuchi A, Kawahara M, Tomita K. 2011. Potentiation of the antitumor effect of calcium phosphate cement containing anticancer drug and caffeine on rat osteosarcoma. J Orthop Sci 16: 77-84.
47. Tentner AR, Lee MJ, Ostheimer GJ, Samson LD, Lauffenburger DA, Yaffe MB. 2012. Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress. Mol Syst Biol 31: 568.
48. Ternovoi VV, Curiel DT, Smith BF, Siegal GP. 2006. Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma. Lab Invest 86: 748-766.
49. Thornborrow EC, Patel S, Mastropietro AE, Schwartzfarb EM, Manfredi JJ. 2002. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes. Oncogene 21: 990-999.
50. Tian L, Yin D, Ren Y, Gong C, Chen A, Guo FJ. 2012. Plumbagin induces apoptosis via the p53 pathway and generation of reactive oxygen species in human osteosarcoma cells. Mol Med Report 5: 126-132.
51. Tsakiridis T, Cutz JC, Singh G, Hirte H, Okawara G, Corbett T, Sur R, Cai W, Whelan T, Wright JR. 2008. Association of phosphorylated epidermal growth factor receptor with survival in patients with locally advanced non-small cell lung cancer treated with radiotherapy. J Thorac Oncol 3: 716-722.
52. Varmeh S, Manfredi JJ. 2008. Overexpression of the dual specificity phosphatase, Cdc25C, confers sensitivity on tumor cells to doxorubicin-induced cell death. Mol Cancer Ther 7: 3789-3799.
53. Yoshiko Y, Candeliere GA, Maeda N, Aubin JE. 2007. Osteoblast autonomous Pi regulation via Pit1 plays a role in bone mineralization. Mol Cell Biol 27: 4465-4474.
54. Yuan XW, Zhu XF, Huang XF, Sheng PY, He AS, Yang ZB, Deng R, Feng GK, Liao WM. 2007. Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis. Acta Pharmacol Sin 28: 1835-1841.
55. Zhuang S, Schnellmann RG. 2006. A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther 319: 991-997.
56. Zou J, Gan M, Mao N, Zhu X, Shi Q, Yang H. 2010. Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by downregulating survivin. Arch Med Res 41: 162-169.
57. Zucchini C, Bianchini M, Valvassori L, Perdichizzi S, Benini S, Manara MC, Solmi R, Strippoli P, Picci P, Carinci P, Scotlandi K. 2004. Identification of candidate genes involved in the reversal of malignant phenotype of osteosarcoma cells transfected with the liver/bone/kidney alkaline phosphatase gene. Bone 34: 672-679.